Biomedicine is making progress in its understanding of the mechanisms of biology and disease through the gradual transition from an era of genome sequencing and functional annotation towards an era of genome information utilization. However, many pre-genome technologies are encountering problems in answering post genome questions. This has created demand for smaller, faster, cheaper, more accurate and more direct tools to address today's challenges from biopathogen detection, new drug target discovery to system biology, personalized and preventive medicine.

BioNanomatrix (BNM) is a bionanotech designer and maker of nanostructured chips, devices and systems for fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single cell / single molecule level. Currently, BNM develops nanodevices and systems for cancer diagnostics, complex disease therapeutics and personalized medicine on its NANOANALYZER™ platform.

Molecular diagnostics is a 600 million dollar market while complex diseases such as schizophrenia cost 40 billion dollars a year in the US alone.

Borne of a multi-million dollar Department of Defense project funded by DARPA (Defense Advanced Research Project Agency) at Princeton University, BioNanomatrix is currently one of seven platform startups of Princeton University as it builds upon an already strong portfolio of patents and other intellectual property.